(0.28%) 5 114.31 points
(0.39%) 38 387 points
(0.35%) 15 983 points
(-1.61%) $82.50
(5.10%) $2.02
(0.28%) $2 353.70
(0.20%) $27.59
(4.07%) $959.60
(-0.19%) $0.933
(-0.34%) $10.99
(-0.52%) $0.796
(1.70%) $93.44
Quarter results tomorrow
(amc 2024-04-30)
Expected move: +/- 5.00%
0.44% $ 23.81
@ $23.79
Ausgestellt: 29 Apr 2024 @ 20:03
Rendite: 0.08%
Vorheriges Signal: Apr 29 - 19:31
Vorheriges Signal:
Rendite: -0.08 %
Live Chart Being Loaded With Signals
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States...
Stats | |
---|---|
Tagesvolumen | 650 266 |
Durchschnittsvolumen | 2.24M |
Marktkapitalisierung | 7.02B |
EPS | $0 ( 2024-02-06 ) |
Nächstes Ertragsdatum | ( $0.280 ) 2024-04-30 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 36.62 |
ATR14 | $0.295 (1.24%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-21 | Garber Alan M | Buy | 23 491 | Common Stock |
2024-03-21 | Garber Alan M | Sell | 19 205 | Common Stock |
2024-03-21 | Garber Alan M | Sell | 23 491 | Option (right to buy) |
2024-02-23 | Peterson Amy C. | Buy | 82 121 | Common Stock |
2024-02-23 | Aftab Dana | Buy | 63 350 | Common Stock |
INSIDER POWER |
---|
27.66 |
Last 94 transactions |
Buy: 3 435 845 | Sell: 2 083 268 |
Volumen Korrelation
Exelixis Inc Korrelation
10 Am meisten positiv korreliert | |
---|---|
NVEI | 0.902 |
ARRW | 0.897 |
ARDX | 0.891 |
NBST | 0.891 |
LCYAU | 0.889 |
EBACU | 0.888 |
LCY | 0.886 |
RCII | 0.882 |
DAKT | 0.882 |
JNCE | 0.879 |
10 Am meisten negativ korreliert | |
---|---|
GCBC | -0.91 |
SRCE | -0.895 |
GSBC | -0.895 |
HTBK | -0.887 |
ORPH | -0.886 |
BMRC | -0.885 |
SFST | -0.884 |
EQBK | -0.883 |
PTVE | -0.883 |
BWB | -0.883 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Exelixis Inc Korrelation - Währung/Rohstoff
Exelixis Inc Finanzdaten
Annual | 2023 |
Umsatz: | $1.83B |
Bruttogewinn: | $1.76B (96.04 %) |
EPS: | $0.650 |
FY | 2023 |
Umsatz: | $1.83B |
Bruttogewinn: | $1.76B (96.04 %) |
EPS: | $0.650 |
FY | 2022 |
Umsatz: | $1.61B |
Bruttogewinn: | $1.55B (96.41 %) |
EPS: | $0.570 |
FY | 2021 |
Umsatz: | $1.43B |
Bruttogewinn: | $1.38B (96.32 %) |
EPS: | $0.733 |
Financial Reports:
No articles found.
Exelixis Inc
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.